SVMC Holdings, INC

SVMC Holdings, INC was paid $131.51M by Medicaid between Jan 2018 and Dec 2024, across 466 billing codes. Its largest line is 99285, emergency room visit (most serious) — 23% of everything it billed.

33Billing provider infoSVMC HOLDINGS, INC
BRIDGEPORT, CT 06606

33aNPI1942224696assigned 07/26/2006

33bProvider typeGeneral Acute Care Hospital

28Total paid$131.51M

24GClaims2,572,004

24DCodes billed466

24AFirst – last monthJan 2018 – Dec 2024

Compared with peers

Next to other General Acute Care Hospital providers in Connecticut

Rank by total paid#5 of 18

Median peer was paid$15.60M

This provider vs. median8.4×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	319,990	$17.38M
2019	329,248	$17.18M
2020	268,446	$12.95M
2021	377,024	$17.96M
2022	418,661	$21.44M
2023	446,139	$22.39M
2024incomplete	412,496	$22.21M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99285	Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life	23%	66,607	57,936	$30.23M
99284	Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity	12%	53,711	46,998	$16.33M
99283	Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity	10%	63,618	55,446	$13.38M
96374	Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance	5.8%	53,677	44,374	$7.58M
S9480	Intensive outpatient psychiatric services, per diem	3.6%	42,597	6,510	$4.70M
93306	Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete	2.8%	12,986	12,124	$3.72M
43239	Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple	2.5%	5,358	5,079	$3.25M
78452	Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress	2.2%	4,692	4,382	$2.90M
74177	Computed tomography, abdomen and pelvis; with contrast material	1.9%	12,305	11,202	$2.53M
97110	Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion	1.6%	33,060	10,517	$2.06M
70450	Computed tomography, head or brain; without contrast material	1.5%	16,699	14,929	$2.01M
96361	Intravenous infusion, hydration; each additional hour	1.4%	34,435	27,470	$1.87M

454 more codes

G0463	Hospital outpatient clinic visit for assessment and management of a patient	1.4%	24,795	$1.82M
99291	Critical care, evaluation and management of the critically ill patient, first 30-74 minutes	1.3%	2,531	$1.75M
45380	Colonoscopy, flexible; with biopsy, single or multiple	1.2%	1,701	$1.58M
96365	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	1.2%	12,156	$1.53M
99282	Emergency department visit for the evaluation and management, low to moderate severity	1.2%	11,805	$1.52M
96360	Intravenous infusion, hydration; initial, 31 minutes to 1 hour	1.2%	10,797	$1.51M
45385	Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s)	1.1%	1,780	$1.42M
11042	Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm	1.1%	8,781	$1.41M
96375	Therapeutic injection; each additional sequential IV push	1.1%	34,374	$1.39M
71046	Radiologic examination, chest; 2 views	<1%	22,327	$1.31M
J9271	Injection, pembrolizumab, 1 mg	<1%	197	$1.31M
93458		<1%	952	$1.31M
J1439	Injection, ferric carboxymaltose, 1 mg	<1%	1,820	$1.10M
96413	Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance	<1%	5,092	$1.02M
71045	Radiologic examination, chest; single view	<1%	21,218	$997K
74176	Computed tomography, abdomen and pelvis; without contrast material	<1%	7,303	$964K
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	<1%	14,860	$942K
G0379	Direct admission of patient for hospital observation care	<1%	1,660	$792K
47562		<1%	179	$738K
J0897	Injection, denosumab, 1 mg	<1%	713	$728K
0241U	Neonatal screening for hereditary disorders, genomic sequence analysis panel	<1%	6,485	$726K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	5,946	$612K
77067	Screening mammography, bilateral, including computer-aided detection	<1%	5,487	$585K
27447		<1%	126	$491K
71275	Computed tomographic angiography, chest, with contrast material	<1%	3,635	$456K
45378	Colonoscopy, flexible; diagnostic, including collection of specimen(s)	<1%	749	$447K
59025	Fetal non-stress test	<1%	2,659	$433K
93350		<1%	1,014	$401K
76801		<1%	3,590	$378K
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	<1%	5,092	$362K
G0121	Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk	<1%	448	$354K
93017		<1%	8,534	$351K
76830	Ultrasound, transvaginal	<1%	3,368	$341K
71260	Computed tomography, thorax, diagnostic; with contrast material	<1%	2,477	$325K
97112	Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination	<1%	23,177	$318K
76641		<1%	3,499	$318K
76705	Ultrasound, abdominal, real time with image documentation; limited	<1%	3,167	$290K
93798		<1%	3,991	$280K
90791	Psychiatric diagnostic evaluation	<1%	2,625	$254K
93971		<1%	3,596	$247K
97161		<1%	5,035	$233K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	<1%	11,320	$226K
93976		<1%	2,126	$211K
76700	Ultrasound, abdominal, real time with image documentation; complete	<1%	2,185	$195K
93975		<1%	828	$181K
93351		<1%	427	$179K
76856	Ultrasound, pelvic (nonobstetric), real time with image documentation; complete	<1%	2,062	$177K
76811	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed	<1%	796	$164K
10061		<1%	529	$153K
93970		<1%	1,180	$150K
96366	Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour	<1%	4,314	$149K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	3,391	$144K
90792	Psychiatric diagnostic evaluation with medical services	<1%	1,394	$143K
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	<1%	4,035	$134K
90853	Group psychotherapy (other than of a multiple-family group)	<1%	12,663	$134K
76816	Ultrasound, pregnant uterus, real time with image documentation, follow-up	<1%	1,495	$133K
97597		<1%	1,809	$131K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	<1%	1,121	$129K
77065	Tomosynthesis, mammo	<1%	1,179	$128K
70551	Magnetic resonance imaging, brain; without contrast material	<1%	907	$125K
86900		<1%	11,287	$119K
95810	Polysomnography; sleep staging with 4 or more additional parameters	<1%	209	$119K
96372	Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular	<1%	18,950	$107K
97162		<1%	1,997	$106K
71250		<1%	2,431	$105K
76642		<1%	1,641	$104K
29580		<1%	1,614	$103K
78815	Positron emission tomography (PET) for limited area imaging	<1%	148	$101K
0202U	Oncology (prostate), multianalyte, gene expression profiling	<1%	280	$98K
97140	Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage)	<1%	22,605	$92K
97530	Therapeutic activities, direct patient contact, each 15 minutes	<1%	12,016	$91K
96415		<1%	1,377	$90K
0002A		<1%	2,874	$88K
0001A		<1%	3,103	$87K
96367		<1%	1,871	$87K
72148	Magnetic resonance imaging, lumbar spine; without contrast material	<1%	551	$83K
90832	Psychotherapy session, about 30 minutes	<1%	3,112	$82K
76805	Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation	<1%	721	$78K
77066	Tomosynthesis, mammo	<1%	639	$76K
77063	Screening digital breast tomosynthesis, bilateral	<1%	5,385	$76K
72100		<1%	4,108	$73K
99214	Doctor's office visit, returning patient (more involved)	<1%	1,842	$72K
C8929	Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography	<1%	294	$69K
80053	Comprehensive metabolic panel	<1%	62,215	$67K
85025	Blood count; complete (CBC), automated, and automated differential WBC count	<1%	121,642	$66K
96417		<1%	1,225	$65K
15271		<1%	69	$63K
77336		<1%	881	$59K
76857		<1%	626	$58K
90834	Psychotherapy session, about 45 minutes	<1%	1,257	$56K
70553	Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences	<1%	211	$56K
70496		<1%	409	$56K
97010		<1%	992	$56K
72125	Computed tomography, cervical spine; without contrast material	<1%	6,656	$55K
36430		<1%	382	$54K
76770		<1%	655	$53K
99281	Emergency department visit for the evaluation and management, self-limited or minor	<1%	694	$48K
Q5106	Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units	<1%	587	$47K
93005	Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report	<1%	52,992	$47K
97165		<1%	825	$45K
97116		<1%	1,818	$44K
72131		<1%	1,527	$44K
G0498	Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted living) using a portable pump provided by the office/clinic, includes follow up office/clinic visit at the conclusion of the infusion	<1%	320	$41K
Q0222	Injection, bebtelovimab, 175 mg	<1%	161	$41K
73630		<1%	3,714	$39K
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	1,048	$38K
73560		<1%	5,255	$38K
82728		<1%	6,108	$38K
74174		<1%	243	$35K
Q5108	Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg	<1%	21	$35K
Q0138	Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use)	<1%	183	$34K
90833	Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on)	<1%	1,160	$33K
94060		<1%	168	$32K
M0222	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	<1%	160	$32K
P9016	Red blood cells, leukocytes reduced, each unit	<1%	296	$31K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	3,234	$29K
76536		<1%	436	$29K
70486		<1%	1,769	$29K
92507	Treatment of speech, language, voice, communication, and/or auditory processing disorder	<1%	479	$29K
99213	Doctor's office visit, returning patient (routine)	<1%	710	$29K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	3,215	$28K
90837	Psychotherapy session, about an hour	<1%	306	$27K
77334		<1%	94	$26K
11043		<1%	76	$24K
83550		<1%	5,847	$24K
82607		<1%	3,449	$24K
96402		<1%	906	$24K
72040		<1%	1,813	$24K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	<1%	200	$21K
96411		<1%	499	$20K
73030		<1%	4,007	$20K
M0245	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	<1%	67	$20K
76815	Ultrasound, pregnant uterus, real time with image documentation, limited	<1%	2,062	$19K
C9803	Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	22,284	$19K
83540		<1%	6,153	$18K
G2066	Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results	<1%	1,366	$18K
72132		<1%	712	$17K
73502		<1%	2,168	$17K
97535	Self-care/home management training, each 15 minutes	<1%	2,153	$17K
J0185	Injection, aprepitant, 1 mg	<1%	150	$17K
73610		<1%	3,040	$15K
73700		<1%	274	$15K
82746		<1%	1,791	$13K
36415	Collection of venous blood by venipuncture	<1%	70,246	$13K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	<1%	136	$13K
74240		<1%	99	$12K
70491		<1%	81	$12K
74183		<1%	65	$12K
93296		<1%	1,152	$11K
73130		<1%	3,574	$11K
93312		<1%	82	$11K
73721	Magnetic resonance imaging, any joint of lower extremity; without contrast material	<1%	40	$10K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	<1%	12,398	$9K
C9088	Instillation, bupivacaine and meloxicam, 1 mg/0.03 mg	<1%	83	$9K
72141		<1%	62	$9K
99215	Doctor's office visit, returning patient (complex)	<1%	74	$9K
80048	Basic metabolic panel (calcium, ionized)	<1%	59,101	$8K
83615		<1%	3,621	$8K
G0378	Hospital observation service, per hour	<1%	14,459	$8K
86923		<1%	588	$8K
78451		<1%	36	$7K
72128		<1%	578	$7K
84443	Thyroid stimulating hormone (TSH)	<1%	12,188	$7K
93298		<1%	516	$7K
97166		<1%	91	$6K
0004A		<1%	298	$6K
12001		<1%	1,130	$6K
M0247	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	<1%	22	$6K
73110		<1%	1,841	$6K
0064A		<1%	163	$6K
77300		<1%	57	$5K
82306	Vitamin D; 25 hydroxy, includes fraction(s), if performed	<1%	386	$5K
72070		<1%	310	$5K
36591		<1%	266	$5K
94640	Pressurized or nonpressurized inhalation treatment for acute airway obstruction	<1%	10,670	$4K
93297		<1%	275	$4K
97163		<1%	84	$4K
76817	Ultrasound, pregnant uterus, real time with image documentation, transvaginal	<1%	2,392	$4K
77080		<1%	38	$4K
M0243	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring	<1%	16	$4K
80076		<1%	29,146	$4K
83735		<1%	24,861	$4K
74018		<1%	1,591	$4K
87641		<1%	948	$3K
12011		<1%	494	$3K
82378		<1%	822	$3K
82784		<1%	332	$3K
84165		<1%	659	$3K
0012A		<1%	131	$3K
0031A		<1%	132	$3K
77061		<1%	233	$3K
10060		<1%	20	$3K
77085		<1%	44	$3K
86320		<1%	302	$2K
83521		<1%	377	$2K
93290		<1%	180	$2K
0011A		<1%	115	$2K
73070		<1%	592	$2K
83036	Hemoglobin; glycosylated (A1C)	<1%	2,304	$2K
86850		<1%	11,091	$2K
74019		<1%	581	$2K
93242		<1%	101	$2K
83880		<1%	12,186	$2K
80061	Lipid panel	<1%	241	$2K
81025		<1%	31,518	$2K
88305	Level IV - Surgical pathology, gross and microscopic examination	<1%	12,644	$2K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	3,333	$2K
87502	Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets	<1%	24	$2K
G0279	Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)	<1%	1,289	$2K
85610		<1%	19,728	$2K
74021		<1%	837	$2K
85730		<1%	6,543	$2K
84134		<1%	458	$2K
72110		<1%	27	$2K
73590		<1%	1,070	$1K
86901		<1%	11,283	$1K
97035		<1%	27	$1K
71101		<1%	475	$1K
84439		<1%	1,541	$1K
12002		<1%	302	$1K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	14,488	$1K
87070		<1%	3,755	$1K
76813		<1%	1,454	$1K
0003A		<1%	33	$1K
87186		<1%	5,425	$1K
76870		<1%	173	$1K
87086	Culture, bacterial; quantitative colony count, urine	<1%	8,828	$965.68
81003		<1%	45,106	$941.06
85651		<1%	1,585	$929.19
73562		<1%	41	$894.16
82947		<1%	476	$869.24
77062		<1%	73	$869.20
88342		<1%	657	$843.93
0071A		<1%	22	$800.00
85045		<1%	492	$780.84
86140		<1%	1,364	$768.76
0124A		<1%	26	$760.00
0072A		<1%	21	$760.00
85027		<1%	5,873	$750.18
84484		<1%	41,614	$721.89
87088		<1%	6,539	$681.44
88307		<1%	1,305	$660.42
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	784	$659.97
86920		<1%	33	$645.40
29581		<1%	18	$633.31
72170		<1%	870	$632.92
84702		<1%	3,655	$622.52
83690		<1%	34,713	$617.24
82565		<1%	3,738	$609.20
90715		<1%	1,987	$587.05
36600		<1%	477	$559.95
97150	Therapeutic procedure(s), group (2 or more individuals)	<1%	350	$545.78
87205		<1%	3,841	$529.94
87075		<1%	810	$527.79
93880		<1%	12	$472.15
70498		<1%	393	$452.34
87077		<1%	4,386	$416.91
83883		<1%	62	$415.36
87400		<1%	9,987	$409.82
0034A		<1%	12	$400.00
83605		<1%	18,444	$385.31
82805		<1%	4,934	$352.37
90471	Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine	<1%	2,332	$315.46
87081		<1%	3,386	$312.55
94726		<1%	106	$310.80
86334		<1%	41	$306.42
86780		<1%	30	$303.36
73090		<1%	380	$298.54
J1756	Injection, iron sucrose, 1 mg	<1%	1,420	$292.00
73080		<1%	233	$270.34
J7030	Infusion, normal saline solution , 1000 cc	<1%	65,325	$266.77
J3490	Unclassified drugs	<1%	250,413	$264.29
82570		<1%	356	$261.82
81001		<1%	10,230	$239.24
90686		<1%	43	$237.36
Q9967	Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml	<1%	22,228	$217.29
87040		<1%	6,986	$208.53
J0136	Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg	<1%	392	$205.30
29125		<1%	332	$200.99
88313		<1%	3,424	$194.21
J2310	Injection, naloxone hydrochloride, per 1 mg	<1%	14	$185.40
73060		<1%	27	$182.42
J0134	Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg	<1%	1,314	$178.52
73140		<1%	24	$174.66
20561		<1%	32	$167.10
90460	Immunization administration through 18 years of age via any route, first or only component	<1%	87	$162.00
84156		<1%	264	$157.50
88304		<1%	1,804	$145.27
82550		<1%	6,190	$139.63
85379		<1%	3,275	$129.82
96376		<1%	8,117	$119.17
86618		<1%	130	$113.89
84100		<1%	4,975	$110.70
82248		<1%	146	$103.21
84703		<1%	606	$100.52
86300		<1%	13	$99.35
83010		<1%	22	$96.08
87880	Infectious agent antigen detection by immunoassay; Streptococcus, group A	<1%	511	$90.84
Q9954	Oral magnetic resonance contrast agent, per 100 ml	<1%	2,513	$90.44
84550		<1%	1,302	$88.02
70360		<1%	13	$69.46
J1885	Injection, ketorolac tromethamine, per 15 mg	<1%	39,815	$64.73
84520		<1%	2,856	$63.42
80051		<1%	2,312	$60.30
84152		<1%	12	$52.68
82077		<1%	1,048	$47.45
85014		<1%	249	$45.20
J7120	Ringers lactate infusion, up to 1000 cc	<1%	20,217	$43.84
85018		<1%	377	$42.94
87420		<1%	604	$36.54
83655		<1%	23	$34.68
J0131	Injection, acetaminophen, not otherwise specified,10 mg	<1%	2,710	$32.21
J2930	Injection, methylprednisolone sodium succinate, up to 125 mg	<1%	2,996	$31.84
82150		<1%	785	$30.95
84132		<1%	197	$26.92
J3360	Injection, diazepam, up to 5 mg	<1%	1,870	$26.87
84145		<1%	51	$25.58
J1790	Injection, droperidol, up to 5 mg	<1%	2,138	$22.87
J2270	Injection, morphine sulfate, up to 10 mg	<1%	13,175	$20.24
86308		<1%	544	$18.62
J2405	Injection, ondansetron hydrochloride, per 1 mg	<1%	31,160	$17.63
J1100	Injection, dexamethasone sodium phosphate, 1 mg	<1%	12,891	$13.97
87184		<1%	500	$13.18
80164		<1%	539	$12.94
J1200	Injection, diphenhydramine hcl, up to 50 mg	<1%	7,531	$11.96
J0690	Injection, cefazolin sodium, 500 mg	<1%	12,099	$11.68
J0696	Injection, ceftriaxone sodium, per 250 mg	<1%	8,298	$10.48
J2001	Injection, lidocaine hcl for intravenous infusion, 10 mg	<1%	23,101	$10.31
J7512	Prednisone, immediate release or delayed release, oral, 1 mg	<1%	6,303	$10.12
Q0144	Azithromycin dihydrate, oral, capsules/powder, 1 gram	<1%	647	$9.96
J7040	Infusion, normal saline solution, sterile (500 ml = 1 unit)	<1%	9,273	$8.79
J0360	Injection, hydralazine hcl, up to 20 mg	<1%	798	$8.40
J2765	Injection, metoclopramide hcl, up to 10 mg	<1%	6,454	$8.06
J3010	Injection, fentanyl citrate, 0.1 mg	<1%	14,114	$7.87
82010		<1%	717	$7.80
J1644	Injection, heparin sodium, per 1000 units	<1%	6,253	$7.75
90472	Immunization administration, each additional vaccine (list separately)	<1%	15	$6.27
J2704	Injection, propofol, 10 mg	<1%	27,778	$5.85
J2250	Injection, midazolam hydrochloride, per 1 mg	<1%	12,887	$5.30
J3475	Injection, magnesium sulfate, per 500 mg	<1%	2,338	$5.28
J0137	Injection, acetaminophen (hikma), not therapeutically equivalent to j0131, 10 mg	<1%	13	$5.00
J1650	Injection, enoxaparin sodium, 10 mg	<1%	1,488	$4.42
J2060	Injection, lorazepam, 2 mg	<1%	4,305	$4.17
J7050	Infusion, normal saline solution, 250 cc	<1%	8,891	$4.06
Q0163	Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen	<1%	3,805	$3.93
Q9957	Injection, perflutren lipid microspheres, per ml	<1%	279	$3.59
J0665	Injection, bupivicaine, not otherwise specified, 0.5 mg	<1%	2,295	$2.90
J1170	Injection, hydromorphone, up to 4 mg	<1%	7,540	$2.68
Q0162	Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen	<1%	4,748	$2.64
J7620	Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme	<1%	3,300	$2.28
J1630	Injection, haloperidol, up to 5 mg	<1%	1,478	$1.98
J8540	Dexamethasone, oral, 0.25 mg	<1%	3,984	$1.82
J0780	Injection, prochlorperazine, up to 10 mg	<1%	1,382	$1.60
G8979	Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting	<1%	200	$1.02
J2003	Injection, lidocaine hydrochloride, 1 mg	<1%	820	$1.00
G8978	Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals	<1%	194	$0.98
90672		<1%	45	$0.40
J1836	Injection, metronidazole, 10 mg	<1%	264	$0.32
J7510	Prednisolone oral, per 5 mg	<1%	476	$0.22
90670		<1%	24	$0.20
J7613	Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg	<1%	1,391	$0.04
88312		0%	6,477	$0.00
99152		0%	2,673	$0.00
J0692	Injection, cefepime hydrochloride, 500 mg	0%	26	$0.00
C1776	Joint device (implantable)	0%	824	$0.00
C1887	Catheter, guiding (may include infusion/perfusion capability)	0%	1,039	$0.00
93356		0%	111	$0.00
82009		0%	648	$0.00
C1713	Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable)	0%	1,442	$0.00
J9190	Injection, fluorouracil, 500 mg	0%	696	$0.00
0055T		0%	31	$0.00
J3370	Injection, vancomycin hcl, 500 mg	0%	1,568	$0.00
S0164	Injection, pantoprazole sodium, 40 mg	0%	138	$0.00
72129		0%	512	$0.00
80143		0%	130	$0.00
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	0%	33	$0.00
J0171	Injection, adrenalin, epinephrine, 0.1 mg	0%	120	$0.00
94729		0%	148	$0.00
93325		0%	76	$0.00
76376		0%	62	$0.00
A9552	Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries	0%	108	$0.00
J2710	Injection, neostigmine methylsulfate, up to 0.5 mg	0%	32	$0.00
C1894	Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser	0%	2,247	$0.00
J2272	Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg	0%	218	$0.00
C1760	Closure device, vascular (implantable/insertable)	0%	184	$0.00
J1596	Injection, glycopyrrolate, 0.1 mg	0%	902	$0.00
85347		0%	184	$0.00
91300		0%	5,783	$0.00
J1245	Injection, dipyridamole, per 10 mg	0%	907	$0.00
J0640	Injection, leucovorin calcium, per 50 mg	0%	682	$0.00
J2919	Injection, methylprednisolone sodium succinate, 5 mg	0%	410	$0.00
80179		0%	127	$0.00
J0295	Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm	0%	16	$0.00
J0670	Injection, mepivacaine hydrochloride, per 10 ml	0%	17	$0.00
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	0%	102	$0.00
J9263	Injection, oxaliplatin, 0.5 mg	0%	50	$0.00
J1171	Injection, hydromorphone, 0.1 mg	0%	258	$0.00
J2004	Injection, lidocaine hcl with epinephrine, 1 mg	0%	35	$0.00
Q9966	Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml	0%	25	$0.00
90461		0%	45	$0.00
C1729	Catheter, drainage	0%	14	$0.00
51702		0%	12	$0.00
91312		0%	13	$0.00
J2370	Injection, phenylephrine hcl, up to 1 ml	0%	2,849	$0.00
96040		0%	314	$0.00
J1940	Injection, furosemide, up to 20 mg	0%	1,671	$0.00
C9290	Injection, bupivacaine liposome, 1 mg	0%	981	$0.00
C1769	Guide wire	0%	2,926	$0.00
A9500	Technetium tc-99m sestamibi, diagnostic, per study dose	0%	4,960	$0.00
99153	Mod sedat endo service >5yrs	0%	2,308	$0.00
J1815	Injection, insulin, per 5 units	0%	6,289	$0.00
J2785	Injection, regadenoson, 0.1 mg	0%	2,997	$0.00
J3420	Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg	0%	2,614	$0.00
A9585	Injection, gadobutrol, 0.1 ml	0%	1,422	$0.00
A9579	Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml	0%	510	$0.00
C1781	Mesh (implantable)	0%	132	$0.00
11045		0%	566	$0.00
J3480	Injection, potassium chloride, per 2 meq	0%	1,557	$0.00
90698		0%	21	$0.00
J7060	5% dextrose/water (500 ml = 1 unit)	0%	2,492	$0.00
J0280	Injection, aminophyllin, up to 250 mg	0%	989	$0.00
J0330	Injection, succinylcholine chloride, up to 20 mg	0%	819	$0.00
J2371	Injection, phenylephrine hydrochloride, 20 micrograms	0%	993	$0.00
C2617	Stent, non-coronary, temporary, without delivery system	0%	62	$0.00
91303		0%	82	$0.00
96368		0%	499	$0.00
J2305	Injection, nitroglycerin, 5 mg	0%	252	$0.00
88341		0%	217	$0.00
A6213	Foam dressing, wound cover, sterile, pad size more than 16 sq. in. but less than or equal to 48 sq. in., with any size adhesive border, each dressing	0%	245	$0.00
J3535	Drug administered through a metered dose inhaler	0%	126	$0.00
90674		0%	19	$0.00
91305		0%	26	$0.00
J1920	Injection, labetalol hydrochloride, 5 mg	0%	344	$0.00
91307		0%	43	$0.00
G0008	Administration of influenza virus vaccine	0%	111	$0.00
91301		0%	260	$0.00
A4648	Tissue marker, implantable, any type, each	0%	119	$0.00
73552		0%	29	$0.00
J2470	Injection, pantoprazole sodium, 40 mg	0%	99	$0.00
C1889	Implantable/insertable device, not otherwise classified	0%	12	$0.00
J7626	Budesonide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, up to 0.5 mg	0%	61	$0.00
91306		0%	158	$0.00
Q2035	Influenza virus vaccine, split virus, when administered to individuals 3 years of age and older, for intramuscular use (afluria)	0%	13	$0.00
87449		0%	13	$0.00
Q0247	Injection, sotrovimab, 500 mg	0%	23	$0.00
87807		0%	132	$0.00
88300		0%	13	$0.00
C1725	Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability)	0%	29	$0.00
C1726	Catheter, balloon dilatation, non-vascular	0%	16	$0.00
J7999	Compounded drug, not otherwise classified	0%	53	$0.00
Q3014	Telehealth originating site facility fee	0%	13	$0.00
74420		0%	17	$0.00
88311		0%	19	$0.00
J2795	Injection, ropivacaine hydrochloride, 1 mg	0%	13	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSLYWKA, ROSEANN (DIRECTOR OF PT. FINANCIAL SERVICES)